Please reload

Recent Posts

Hans Petter Tjeldflaat has joined Biovotec AS as part-time CFO on the 29th of February. Hans Petter has a broad experience from similar positions in s...

Hans Petter Tjeldflaat Joins Biovotec As Part-time CFO

March 3, 2016

1/1
Please reload

Featured Posts

Safety Study Of Final Product Has Started And Is Proceeding Well

September 8, 2016

As a final product testing step before conducting human clinical trials, safety studies have now been initiated. Those safety studies are supervised by the Clinical Research Organization (CRO)  – NAMSA.

 

NAMSA is one of the most prestigious CRO’s in wound care and has performed an estimated 40 – 50%  of all trials on new wound care  products in Europe. As our product consist of animal derived material and is applied for longer than 28 days the most stringent safety trials are applied including long term studies. The already obtained results are all positive.

 

“To enter these safety studies is a major milestone for Biovotec in many aspects, as we are testing a product as it will be sold afterwards – this means that we have completed the build up of a commercial supply chain. In addition; this is the last step before applying to the ethics committee in the UK to enter human trials in the spring of 2017.” - Ralf Schmidt, Co founder Biovotec AS


The trials will also include studies on pig skin which is very similar to human skin.

Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags
Please reload

Archive
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Engebrets vei 3, 0275 Oslo, Norway                                                   © Biovotec AS                                                                       info@biovotec